Tests chemotherapy drugs before surgery for high-risk prostate cancer
Tests chemotherapy drugs given before surgery in men with high-risk prostate cancer.
Plain-language title generated from the registry record
Registry title: A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Key facts
- Where
- Qingdao and Shanghai, ChinaSee the 2 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT03258320, who can take part
Where in China
- Qilu Hospital of Shandong UniversityQingdao, ChinaTaking people
- Zhongshan HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT03258320
- Record updated
- 12 January 2026
- Original description
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.Read full original descriptionShow less
A Phase II-III Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Prostate Cancer
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
Inclusion: 40 ≤ age ≤ 75 years with histologically proven PCa; no severe major organ dysfunction; WHO performance status of 0 or 1; no prior cancer chemotherapy; A Clinical Stage ≥ T2c (T2c, N0, M0) of prostate cancer but ideally without diagnosed distant metastasis (according to the 2016 American Joint Committee on Cancer (AJCC) definition of TNM staging system, Staging Manual, Eighth Edition) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.
Exclusion: prior cancer chemotherapy; age ≥ 76; severe major organ dysfunction; WHO performance status of >1; Stage IV.